565446-50-6

Upstream product

• 81282-38-4 N-diphenoxymethylene benzamide 
• 195053-89-5 4-(3-aminopropyl)-1-(triphenylmethyl)-imidazole 
• 96797-15-8 N-trityl-4⁽⁵⁾-iodoimidazole 
• 154312-79-5 1-trityl-4-(2-cyanoethyl)imidazole 
• 565446-44-8 3-(1-Trityl-1H-imidazol-4-yl)-propionitrile 
• 152030-49-4 3-(1-trityl-1H-imidazol-4-yl)propan-1-ol 
• 33016-47-6 (1-tritylimidazol-4-yl)carboxaldehyde 
• 195053-88-4 2-[3-(1-trityl-1H-imidazol-4-yl)propyl]isoindoline-1,3-dione 

Downstream Products

• 565446-52-8 N-benzoyl-N'-(2-hydroxyethyl)-N-{3-[(1-triphenylmethyl)-imidazol-4-yl]propyl}guanidine 
• 565446-54-0 N-benzoyl-N'-(3-hydroxypropyl)-N-{3-[(1-triphenylmethyl)-imidazol-4-yl]propyl}guanidine 
• 565446-60-8 N-benzoyl-N'-[2-(4-phenyl-furazan-3-yloxy)-ethyl]-N''-[3-(1-trityl-1H-imidazol-4-yl)-propyl]-guanidine 
• 565446-64-2 N-benzoyl-N'-[3-(4-phenyl-furazan-3-yloxy)-propyl]-N''-[3-(1-trityl-1H-imidazol-4-yl)-propyl]-guanidine 
• 565446-62-0 N-benzoyl-N'-[2-(5-oxy-4-phenyl-furazan-3-yloxy)-ethyl]-N''-[3-(1-trityl-1H-imidazol-4-yl)-propyl]-guanidine 
• 565446-65-3 N-benzoyl-N'-[3-(5-oxy-4-phenyl-furazan-3-yloxy)-propyl]-N''-[3-(1-trityl-1H-imidazol-4-yl)-propyl]-guanidine 
• 565446-67-5 N-[3-(4-benzenesulfonyl-furazan-3-yloxy)-propyl]-N'-benzoyl-N''-[3-(1-trityl-1H-imidazol-4-yl)-propyl]-guanidine 
• 565446-69-7 N-[3-(4-benzenesulfonyl-5-oxy-furazan-3-yloxy)-propyl]-N'-benzoyl-N''-[3-(1-trityl-1H-imidazol-4-yl)-propyl]-guanidine 
• 565446-52-8 N-benzoyl-N'-(2-hydroxy-ethyl)-N''-[3-(1-trityl-1H-imidazol-4-yl)-propyl]-guanidine 
• 565446-54-0 N-benzoyl-N'-(3-hydroxy-propyl)-N''-[3-(1-trityl-1H-imidazol-4-yl)-propyl]-guanidine 
• 565446-60-8 N-benzoyl-N'-[2-(4-phenyl-furazan-3-yloxy)-ethyl]-N''-[3-(1-trityl-1H-imidazol-4-yl)-propyl]-guanidine 
• 565446-64-2 N-benzoyl-N'-[3-(4-phenyl-furazan-3-yloxy)-propyl]-N''-[3-(1-trityl-1H-imidazol-4-yl)-propyl]-guanidine 

Relevant academic research and scientific papers

H3 receptor ligands: New imidazole H3-antagonists endowed with NO-donor properties

Synthesis and pharmacological properties of a group of compounds obtained by coupling the H3-antagonist SKF 91486 with the NO-donor 3-phenylfuroxan-4-yloxy and 3-benzenesulfonylfuroxan-4-yloxy moieties, as well as with the corresponding furazan analogues, devoid of NO-donating properties, are reported. All the products were tested for their H3-antagonistic and H2-agonistic properties on electrically-simulated guinea-pig ileum segments and guinea-pig papillary muscle, respectively. All the synthesised compounds displayed good H3-antagonistic properties (pA2 range 7.02-8.49) while behaving only as weak partial H2-agonists. Derivative 28, the best NO-donor of the series, was able to trigger a dual NO-dependent muscle relaxation and H3-antagonistic effect on guinea-pig illeum.

[3-(1H-Imidazol-4-yl)propyl]guanidines containing furoxan moieties: A new class of H3-antagonists endowed with NO-donor properties

Synthesis and pharmacological characterisation of a series of products obtained by coupling the H3-antagonist SKF 91486 through appropriate spacers with the NO-donor 3-phenylfuroxan-4-yloxy and 3-benzenesulfonylfuroxan-4-yloxy moieties, as well as with the corresponding furazan substructures, devoid of NO-donating properties, are reported. All the products were tested for their H3-antagonistic and H2-agonistic properties on electrically-stimulated guinea-pig ileum segments and guinea-pig papillary muscle, respectively. The whole series of compounds displayed good H3-antagonist behaviour and feeble partial H2-agonist activity. Among furoxan derivatives, the benzenesulfonyl hybrid 28, a good NO-donor, triggered a dual NO-dependent muscle relaxation and H3-antagonistic effect on guinea-pig intestine.